drugset / Trial / NCT04364399
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of mumps vaccine in healthy infants aged 8-12months, compared with measles, mumps and rubella combined vaccine, live (MMRV).
Timeline
- Start
- 2020-11-18
- Primary completion
- 2020-11-18
- Completion
- 2021-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MUMPS VIRUS VACCINE LIVE | Vaccine | 0.5 ml | — |
| Comparator | measles, mumps and rubella combined vaccine, live | Vaccine | 0.5 ml | — |